Want to see IN:AUROPHARMA full AI Analyst Report?
Top Page
Aurobindo Pharma Ltd
(AUROPHARMA)
Select Model
Select Model
Rating:69Neutral
Price Target:
₹1,774.00
▲(9.37% Upside)
Action:Reiterated
Date:08/23/26
The score is primarily supported by solid financial health (steady growth, conservative leverage, and a strong 2026 free-cash-flow rebound) and constructive technicals (price above key moving averages with positive MACD). This is tempered by weaker valuation support (higher P/E and low dividend yield) and some fundamental watch items such as 2026 margin compression and moderate ROE.
Positive Factors
Steady Revenue Growth
Consistent revenue expansion indicates durable demand across Aurobindo Pharma’s diversified generic formulations and API businesses. Continued growth supports manufacturing utilization, market presence, and the company’s ability to build scale across domestic and regulated international markets.
Negative Factors
Margin Compression
The sharp gross-margin decline indicates that revenue growth is facing pressure from product mix, pricing, input costs, or competitive intensity. If sustained, lower margins could restrict reinvestment capacity and weaken the earnings benefit of expanding pharmaceutical sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Consistent revenue expansion indicates durable demand across Aurobindo Pharma’s diversified generic formulations and API businesses. Continued growth supports manufacturing utilization, market presence, and the company’s ability to build scale across domestic and regulated international markets.
Read all positive factors
Aurobindo Pharma Ltd (AUROPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹958.87B
Dividend Yield0.24%
Average Volume (3M)23.80K
Price to Earnings (P/E)26.2
Beta (1Y)0.65
Revenue Growth9.09%
EPS Growth9.61%
CountryIN
Employees29,209
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)64.00
Shares Outstanding575,377,870
10 Day Avg. Volume32,288
30 Day Avg. Volume23,798
Financial Highlights & Ratios
PEG Ratio24.40
Price to Book (P/B)2.00
Price to Sales (P/S)2.25
P/FCF Ratio26.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)79.65
Revenue Forecast (FY)₹400.79B
Aurobindo Pharma Ltd Business Overview & Revenue Model
Company Description
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liq...
How the Company Makes Money
Aurobindo Pharma makes money mainly by selling pharmaceutical products across multiple markets, with revenue primarily generated from (1) finished-dosage formulations and (2) active pharmaceutical ingredients (APIs). Finished-dosage formulations i...
Aurobindo Pharma Ltd Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 348.91B | 336.53B | 317.24B | 290.02B | 248.55B | 234.55B |
| Gross Profit | 156.81B | 131.96B | 182.40B | 160.16B | 132.14B | 130.06B |
| EBITDA | 76.65B | 72.74B | 64.36B | 57.64B | 36.34B | 43.11B |
| Net Income | 37.13B | 35.05B | 34.86B | 31.73B | 19.27B | 26.48B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 585.02B | 497.85B | 450.72B | 398.90B | 339.22B |
| Cash, Cash Equivalents and Short-Term Investments | 105.85B | 106.18B | 82.36B | 63.25B | 62.24B | 45.58B |
| Total Debt | 0.00 | 80.73B | 82.63B | 66.48B | 52.86B | 32.79B |
| Total Liabilities | -378.83B | 206.19B | 171.38B | 152.21B | 130.38B | 93.48B |
| Stockholders Equity | 378.83B | 378.91B | 326.53B | 298.43B | 268.40B | 245.76B |
Cash Flow | ||||||
| Free Cash Flow | 15.22B | 28.27B | 19.57B | -11.27B | -3.34B | 23.12B |
| Operating Cash Flow | 28.85B | 55.13B | 39.25B | 24.35B | 23.87B | 50.16B |
| Investing Cash Flow | -22.23B | -37.89B | -18.76B | -42.56B | -39.78B | -32.12B |
| Financing Cash Flow | -9.43B | -9.25B | 1.20B | 8.00B | 18.14B | -29.69B |
Aurobindo Pharma Ltd Technical Analysis
Positive
1622.00
Price Trends
1643.10
Positive
1574.36
Positive
1414.68
Positive
Market Momentum
14.66
Positive
50.08
Neutral
38.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:AUROPHARMA, the sentiment is Positive. The current price of 1622 is below the 20-day moving average (MA) of 1684.93, below the 50-day MA of 1643.10, and above the 200-day MA of 1414.68, indicating a neutral trend. The MACD of 14.66 indicates Positive momentum. The RSI at 50.08 is Neutral, neither overbought nor oversold. The STOCH value of 38.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:AUROPHARMA.
Aurobindo Pharma Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹1.03T | 30.37 | ― | 0.64% | -0.92% | -41.75% | |
69 Neutral | ₹958.87B | 26.20 | ― | 0.24% | 9.09% | 9.61% | |
69 Neutral | ₹933.79B | 16.79 | ― | 0.89% | 28.19% | 49.25% | |
69 Neutral | ₹4.37T | 35.73 | ― | 0.88% | 11.41% | 16.62% | |
63 Neutral | ₹1.83T | 73.98 | ― | 0.31% | 32.85% | 8.94% | |
57 Neutral | ₹1.16T | 25.53 | ― | 0.09% | 21.11% | -1.28% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,675.00
581.40
53.16%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,200.10
-38.30
-3.09%
IN:LUPIN
Lupin Limited
2,029.00
61.57
3.13%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,810.00
188.66
11.64%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
4,761.95
1,230.08
34.83%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
1,145.25
154.39
15.58%
Aurobindo Pharma Ltd Corporate Events
Aurobindo Pharma’s Lannett Unit Completes Routine U.S. FDA Inspection With Procedural Observations
Aug 24, 2026
Aurobindo Pharma has reported the completion of a routine U.S. FDA inspection at Lannett Company LLC, its wholly owned step-down subsidiary in Seymour, Indiana. The inspection, conducted from August 17 to 21, 2026, resulted in four procedural obse...
Aurobindo’s Raleigh Plant Cleared by USFDA With VAI Classification
Aug 17, 2026
Aurobindo Pharma’s U.S.-based unit Aurolife Pharma has received a Voluntary Action Indicated classification from the USFDA for its Raleigh, North Carolina plant, which manufactures inhalers, dermatology, and transdermal products. The inspect...
Aurobindo Pharma Wins FTC Nod for Lannett Acquisition, Eyes Month-End Closing
Jun 19, 2026
Aurobindo Pharma has secured approval from the U.S. Federal Trade Commission for its planned acquisition of the Lannett business through its subsidiary Aurobindo Pharma USA Inc, clearing a key regulatory hurdle for the deal. The company expects to...
Aurobindo Pharma to Join Goldman Sachs Investor Meet in Hyderabad
Jun 9, 2026
Aurobindo Pharma has informed the stock exchanges that its officials will participate in a group investor meeting organized as part of the Goldman Sachs CRO/CDMO Tour in Hyderabad on June 12, 2026, from 3:30 p.m. to 5:00 p.m. IST. The company note...
Aurobindo Pharma Launches TheraNym Biologics Hub with MSD as Anchor Client
Jun 3, 2026
Aurobindo Pharma has inaugurated TheraNym, a large-scale biologics contract manufacturing facility in Borapatla, near Hyderabad, operated through its subsidiary TheraNym Biologics. The launch underscores the company’s strategic expansion int...
US FDA Flags Aurobindo’s Eugia Unit-I with OAI Classification
May 24, 2026
Aurobindo Pharma has disclosed that the U.S. Food and Drug Administration has classified Unit-I of its wholly owned subsidiary Eugia Pharma Specialities, a formulation manufacturing facility in Shameerpet, Telangana, as “official action indi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.